Retina Consultants San Diego | Poway, CA

Research site

(Unclaimed)

Location

12630 Monte Vista Road, Suite 209, Poway, California, United States of America

Site insights

Top conditions

Top treatments

APL-2

Pegcetacoplan

ABP 938

GT005

Aflibercept

Triamcinolone Acetonide

Bevasiranib

THR-149

JNJ-81201887

Eylea®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 21 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

Wet AMD

Genetic: RGX-314

Biological: Ranibizumab (LUCENTIS®)

Safety and Efficacy of AM712 in Patients With nAMD

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate th...

Enrolling

Neovascular Age-related Macular Degeneration

Biological: AM712(ASKG712)

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (ODYSSEY)

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of supr...

Active, not recruiting

Neovascular Age-related Macular Degeneration

Drug: Aflibercept

Drug: CLS-AX